ArticleOncoimmunology2016
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.
Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis.PloS one · 2017Pooled it
- Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer.Scientific reports · 2025Article
- The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches.Medical oncology (Northwood, London, England) · 2025Review
- Targeting Triple-Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements.Cancer medicine · 2025Review
- Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy.Clinical and experimental medicine · 2024Review
- Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells.Viruses · 2024Article
- Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy.Frontiers in cell and developmental biology · 2024Review
- New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.Frontiers in immunology · 2024Review
- Update on current and new potential immunotherapies in breast cancer, from bench to bedside.Frontiers in immunology · 2024Review
- Review
- Oncolytic viruses: A novel treatment strategy for breast cancer.Genes & diseases · 2023Review
- Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors.NPJ breast cancer · 2022Review
- Article
- Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.Frontiers in oncology · 2022Review
- Viroimmunotherapy for breast cancer: promises, problems and future directions.Cancer gene therapy · 2021Review
- Review
- Prospects of Immunotherapy for Triple-Negative Breast Cancer.Frontiers in oncology · 2021Review
- Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?Frontiers in oncology · 2021Review
- Clinical Trials of Oncolytic Viruses in Breast Cancer.Frontiers in oncology · 2021Review
- The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines.Vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a heterogeneous disease, characterized by several distinct biological subtypes, among which triple-negative breast cancer (TNBC) is one associated with a poor prognosis. Oncolytic virus replication is an immunogenic phenomenon, and viruses can be armed with immunostimulatory molecules to boost virus triggered antitumoral immune responses. Cyclophosphamide (CP) is a chemotherapy drug that is associated with cytotoxicity and immunosuppression at higher doses, whereas immunostimulatory and anti-angiogenic properties are observed at low continuous dosage. Therefore, the combination of oncolytic immuno-virotherapy with low-dose CP is an appealing approach. We investigated the potency of oncolytic adenovirus Ad5/3-D24-GMCSF on a TNBC cell line and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.